Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Completes Dosing of First Cohort in Phase IIb HBV Trial

Premium

Arrowhead Research announced this week that it has completed enrollment and dosing of the first cohort of patients in an ongoing Phase IIb trial of its hepatitis B drug ARC-520.

The open label, single ascending dose study is set to evaluate ARC-520 at doses of 1.0 mg/kg and 2.0 mg/kg. At each of the dose levels tested, 8 patients will be enrolled with 6 receiving ARC-520 and 2 receiving placebo.

The company reiterated its expectation that all patients will be dosed in the second quarter, with top-line results from the study available in the third quarter.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.